200 reports of this reaction
3.1% of all FLUOCINOLONE ACETONIDE reports
#5 most reported adverse reaction
PRODUCT DOSE OMISSION ISSUE is the #5 most commonly reported adverse reaction for FLUOCINOLONE ACETONIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 200 FDA adverse event reports linking FLUOCINOLONE ACETONIDE to PRODUCT DOSE OMISSION ISSUE. This represents approximately 3.1% of all 6,482 adverse event reports for this drug.
Patients taking FLUOCINOLONE ACETONIDE who experience product dose omission issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION ISSUE is moderately reported among FLUOCINOLONE ACETONIDE users, representing a notable but not dominant share of adverse events.
In addition to product dose omission issue, the following adverse reactions have been reported for FLUOCINOLONE ACETONIDE:
The following drugs have also been linked to product dose omission issue in FDA adverse event reports:
PRODUCT DOSE OMISSION ISSUE has been reported as an adverse event in 200 FDA reports for FLUOCINOLONE ACETONIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION ISSUE accounts for approximately 3.1% of all adverse event reports for FLUOCINOLONE ACETONIDE, making it a notable side effect.
If you experience product dose omission issue while taking FLUOCINOLONE ACETONIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.